The GPS result independently identifies likelihood of upgrade onsubsequent biopsy1
In a UCSF study of patients on Active Surveillance who received both the GPS assay and mpMRI, only the GPS assay was independently associated with biopsy upgrade.
In the setting of mpMRI-guided biopsies, the GPS result is a strong independent predictor of adverse pathology2
The predictive values of the GPS result and other clinical factors* were analyzed in patients who received mpMRI-guided and systematic biopsy within 6 months of radical prostatectomy:
Biopsy GS +
Biopsy GS + GPS result + mpMRI
Incorporating mpMRI did not improve predictive value
Use mpMRI and the Oncotype DX GPS assay together for additional clarity
The Oncotype DX GPS assay complements mpMRI usage
mpMRI has the potential to find aggressive disease and reduce the need for invasive biopsies. However, limitations do exist.